Journal article
Dissecting the heterogeneity of triple-negative breast cancer
O Metzger-Filho, A Tutt, E De Azambuja, KS Saini, G Viale, S Loi, I Bradbury, JM Bliss, HA Azim, P Ellis, A Di Leo, J Baselga, C Sotiriou, M Piccart-Gebhart
Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2012
Abstract
Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancers. It is a heterogeneous disease, not only on the molecular level, but also on the pathologic and clinical levels. TNBC is associated with a significantly higher probability of relapse and poorer overall survival in the first few years after diagnosis when compared with other breast cancer subtypes. This is observed despite its usual high sensitivity to chemotherapy. In the advanced setting, responses observed with chemotherapy lack durability. Early-stage clinical studies suggested impressive potential when a poly (ADP-ribose) polymerase (PARP) inhibitor is given for the treatment of advanced TNBC with BRCA gene dy..
View full abstractGrants
Funding Acknowledgements
Employment or Leadership Position: None Consultant or Advisory Role: Andrew Tutt, sanofi-aventis (U), AstraZeneca (U), Eisai (C), Clovis (C); Judith M. Bliss, sanofi-aventis (U); Hatem A. Azim Jr, Celgene (C); Paul Ellis, Roche (C), GlaxoSmithKline (C), sanofi-aventis (C), Esai (C); Angelo Di Leo, AstraZeneca (C), Pfizer (C), sanofi-aventis (C); Jose Baselga, sanofi-aventis (C); Martine Piccart-Gebhart, sanofi-aventis (C), Amgen (C), Roche (C), GlaxoSmithKline (C), PharmaMar (C) Stock Ownership: None Honoraria: Andrew Tutt, AstraZeneca, sanofi-aventis; Paul Ellis, Roche, Esai, sanofi-aventis; Angelo Di Leo, AstraZeneca, Pfizer, sanofi-aventis; Martine Piccart-Gebhart, sanofi-aventis, Amgen, Roche, GlaxoSmithKline, PharmaMar Research Funding: Andrew Tutt, sanofi-aventis; Judith M. Bliss, sanofi-aventis; Angelo Di Leo, AstraZeneca Expert Testimony: None Other Remuneration: Andrew Tutt, AstraZeneca, sanofi-aventis; Judith M. Bliss, sanofi-aventis